-+ 0.00%
-+ 0.00%
-+ 0.00%

Scribe Therapeutics And Prevail To Present New Preclinical Data On siXAAV Technology From Collaboration At ASGCT Annual Meeting

Benzinga·04/28/2025 13:07:55
Listen to the news
  • Success milestone reached in Scribe and Prevail's ongoing collaboration to accelerate in vivo therapeutics for neurological and neuromuscular diseases using Scribe's CRISPR technology
  • Companies to jointly present new preclinical data on self-inactivating AAV (siXAAV) technology from their collaboration at the 28th ASGCT Annual Meeting

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the achievement of a success milestone for one of the targets in its research collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (NYSE:LLY), to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular disorders. The success milestone marks Scribe's second such partnership achievement in 2025.

At the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, the companies will have a joint presentation titled "Self-Targeting CRISPR-CasX-Editor AAV Vectors Enable Potent and Controllable On-target Editing in the Murine CNS." The presentation will take place during the poster reception between 5:30 and 7:00 p.m. CT on Thursday, May 15, 2025, at the New Orleans Ernest N. Morial Convention Center.